You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR1

Showing 1 - 25 of 354
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)

Recruiting
  • Gastrointestinal Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Dec 7, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Palo Alto, California
  • +9 more
Aug 2, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

FGFR Testing by Either ctDNA Blood Testing or Standard Tumor

Recruiting
  • Metastatic Bladder Cancer
  • Metastatic Urothelial Carcinoma
  • FGFR Testing
  • Calgary, Alberta, Canada
  • +6 more
Nov 8, 2023

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Cancer Trial in St. Gallen (Rogaratinib (BAY1163877), Combination drug)

Completed
  • Cancer
  • Rogaratinib (BAY1163877)
  • Combination drug
  • St. Gallen, Sankt Gallen, Switzerland
    Kantonsspital St. Gallen
Mar 20, 2022

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)

Recruiting
  • Achondroplasia
  • Parkville, Victoria, Australia
  • +3 more
Apr 5, 2022

Solid Tumor, Adult Trial in Shanghai (Highly selective FGFR1-3 inhibitor)

Recruiting
  • Solid Tumor, Adult
  • Highly selective FGFR1-3 inhibitor
  • Shanghai, China
    Shanghai East Hospital
Aug 26, 2021

Cholangiocarcinoma Trial in Worldwide (Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice)

Not yet recruiting
  • Cholangiocarcinoma
  • Tinengotinib 8 mg
  • +2 more
  • Santa Monica, California
  • +13 more
Jul 7, 2023

Breast Cancer Metastatic, Hormone Receptor Positive Malignant Tumor of Breast Trial in Spain (Combination, Rogaratinib +

Recruiting
  • Breast Cancer Metastatic
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Combination, Rogaratinib + palbociclib + fulvestrant
  • Hospitalet de Llobregat, Barcelona, Spain
  • +7 more
Feb 8, 2022

Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Phoenix, Arizona
  • +36 more
Jan 27, 2023

MPN (Myeloproliferative Tumors) Trial in Worldwide (Pemigatinib)

Active, not recruiting
  • MPN (Myeloproliferative Neoplasms)
  • Phoenix, Arizona
  • +32 more
Jun 24, 2022

Solid Tumor Trial in Beijing (HMPL-453, gemcitabine and cisplatin, toripalimab)

Recruiting
  • Solid Tumor
  • Beijing, China
    Chinese PLA General Hospital
Mar 4, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Advanced or Metastatic Solid Tumor Trial in Worldwide (Rogaratinib (BAY1163877), Copanlisib (BAY80-6946))

Completed
  • Advanced or Metastatic Solid Tumor
  • Rogaratinib (BAY1163877)
  • Copanlisib (BAY80-6946)
  • Los Angeles, California
  • +19 more
Jul 13, 2022

Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy Trial in Arlington Heights (Panzyga IVIG,

Not yet recruiting
  • Small Fiber Neuropathy
  • +3 more
  • Panzyga IVIG
  • Placebo
  • Arlington Heights, Illinois
    Northwest Community Healthcare
Aug 22, 2022

Advanced Non Small Cell Lung Cancer Trial (Sintilimab, Pemigatinib)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Aug 6, 2021

Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in

Recruiting
  • Locally Advanced Gastrointestinal Stromal Tumor
  • +7 more
  • Biopsy
  • +4 more
  • Duarte, California
  • +17 more
Feb 2, 2023

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022